Lipocine (LPCN)
(Delayed Data from NSDQ)
$4.77 USD
-0.24 (-4.79%)
Updated Sep 19, 2024 03:59 PM ET
After-Market: $4.90 +0.13 (2.73%) 7:04 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Balance Sheet
Fiscal Year End for Lipocine Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 22 | 33 | 45 | 25 | 19 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 2 | 2 | 1 | 1 |
Total Current Assets | 23 | 34 | 46 | 25 | 20 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 2 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 3 | 4 | 0 | 0 |
Total Assets | 23 | 38 | 52 | 25 | 20 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 1 | 1 | 2 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 2 | 3 | 3 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 1 | 1 | 1 | 2 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 1 | 0 | 0 |
Total Current Liabilities | 3 | 2 | 6 | 7 | 5 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 2 | 4 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 1 | 1 | 5 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 3 | 2 | 7 | 10 | 13 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 220 | 219 | 218 | 187 | 157 |
Retained Earnings | -200 | -183 | -173 | -172 | -151 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 20 | 36 | 46 | 15 | 6 |
Total Liabilities & Shareholder's Equity | 23 | 38 | 52 | 25 | 20 |
Total Common Equity | 20 | 36 | 46 | 15 | 6 |
Shares Outstanding | 5.30 | 5.20 | 5.10 | 4.80 | 1.40 |
Book Value Per Share | 3.84 | 6.85 | 8.94 | 3.20 | 4.49 |
Fiscal Year End for Lipocine Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 23 | 25 | 22 | 24 | 26 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 1 | 1 | 1 | 1 |
Total Current Assets | 23 | 25 | 23 | 25 | 27 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 3 |
Total Assets | 23 | 25 | 23 | 25 | 30 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 0 | 1 | 1 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 1 | 1 | 1 | 1 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 2 | 1 | 3 | 2 | 2 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2 | 1 | 3 | 2 | 2 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 221 | 220 | 220 | 220 | 219 |
Retained Earnings | -199 | -196 | -200 | -198 | -191 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 21 | 24 | 20 | 22 | 29 |
Total Liabilities & Shareholder's Equity | 23 | 25 | 23 | 25 | 30 |
Total Common Equity | 21 | 24 | 20 | 22 | 29 |
Shares Outstanding | 5.30 | 5.30 | 5.30 | 5.30 | 5.20 |
Book Value Per Share | 4.00 | 4.52 | 3.84 | 4.24 | 5.49 |